Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Non-Current Assets (2024 - 2025)

Maze Therapeutics has reported Non-Current Assets over the past 2 years, most recently at $47.4 million for Q4 2025.

  • Quarterly Non-Current Assets rose 21.97% to $47.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $143.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $47.4 million for FY2025, 21.97% up from the prior year.
  • Non-Current Assets was $47.4 million for Q4 2025 at Maze Therapeutics, up from $30.8 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $47.4 million in Q4 2025 and troughed at $30.8 million in Q3 2025.